KAKUHIRO YAMAGUCHI

Last Updated :2025/06/10

Affiliations, Positions
Hiroshima University Hospital, Assistant Professor
E-mail
yamakakuhiroshima-u.ac.jp

Basic Information

Academic Degrees

  • Hiroshima University

Affiliated Academic Societies

  • The Japanese Respiratory Society
  • Japanese Society of Medical Oncology
  • The Japan Lung Cancer Society
  • The Japan Society for Respiratoty Endoscopy
  • The Japanese Society of Internal Medicine

Educational Activity

Course in Charge

  1. 2025, Undergraduate Education, Year, Clinical diagnosis and treatment I
  2. 2025, Undergraduate Education, Intensive, Practice of Medicine I
  3. 2025, Undergraduate Education, Intensive, Practice of Medicine II

Research Activities

Academic Papers

  1. Clinical impact of hypomagnesemia induced by necitumumab plus cisplatin and gemcitabine treatment in patients with advanced lung squamous cell carcinoma: a subanalysis of the NINJA study, THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 17, 2025
  2. Predictive Value of Circulatory Total VEGF-A and VEGF-A Isoforms for the Efficacy of Anti-PD-1/PD-L1 Antibodies in Patients with Non-Small-Cell Lung Cancer, CANCERS, 17(4), 202502
  3. Serum Soluble Toll-Like Receptor 4 is a Predictive Biomarker for Acute Exacerbation and Prognosis of Idiopathic Pulmonary Fibrosis: A Retrospective Study, LUNG, 203(1), 202512
  4. Skin disorder within 30 days is a favorable prognostic factor in patients with lung squamous cell carcinoma treated with necitumumab plus gemcitabine and cisplatin: a sub-analysis of the NINJA study, THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 17, 2025
  5. HMGB1 assists the predictive value of tumor PD-L1 expression for the efficacy of anti-PD-1/PD-L1 antibody in NSCLC, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 95(1), 202512
  6. Efficacy of immune checkpoint inhibitors according to programmed cell death-ligand 1 expression in patients with non-small cell lung cancer and brain metastasis: A real-world prospective observational study, THORACIC CANCER, 15(34), 2408-2417, 202412
  7. A Case of Granulocyte-Colony-Stimulating Factor-Producing Non-Small Cell Lung Cancer under Steroid Treatment and with Poor Performance Status That Responded to Pembrolizumab, CASE REPORTS IN ONCOLOGY, 17(1), 1115-1123, 2024
  8. Usefulness of Quantification and Serial Monitoring of Fine Crackles for Early Detection of Treatment-related Lung Injury: A Report of Two Cases, INTERNAL MEDICINE, 63(12), 1783-1787, 2024
  9. Serum soluble isoform of receptor for advanced glycation end product is a predictive biomarker for acute exacerbation of idiopathic pulmonary fibrosis: a German and Japanese cohort study, RESPIRATORY RESEARCH, 25(1), 20241111
  10. Primary pulmonary extranodal NK/T-cell lymphoma diagnosed by thoracoscopic lung biopsy: A case report, RESPIRATORY MEDICINE CASE REPORTS, 52, 2024
  11. Sex-related differences in efficacy of bone marrow-derived high aldehyde dehydrogenase activity cells against pulmonary fibrosis, STEM CELL RESEARCH & THERAPY, 15(1), 20240915
  12. A Case of Miliary Pulmonary Cryptococcosis Showing Different Changes in Computed Tomography Images of the Left and Right Lungs, Respiratory Endoscopy, 202404
  13. Lipocalin-2 as a prognostic marker in patients with acute exacerbation of idiopathic pulmonary fibrosis, RESPIRATORY RESEARCH, 25(1), 20240504
  14. Immune checkpoint inhibitors in patients with lung cancer having chronic interstitial pneumonia, ERJ OPEN RESEARCH, 10(2), 20240301
  15. Intestinal overgrowth of Candida albicans exacerbates bleomycin-induced pulmonary fibrosis in mice with dysbiosis, JOURNAL OF PATHOLOGY, 261(2), 227-237, 202310
  16. Efficacy and Safety of Re-administration of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) After EGFR-TKI-Induced Interstitial Lung Disease (CS-Lung-005), LUNG, 202(1), 63-72, 202402
  17. High S100A9 level predicts poor survival, and the S100A9 inhibitor paquinimod is a candidate for treating idiopathic pulmonary fibrosis, BMJ OPEN RESPIRATORY RESEARCH, 11(1), 202402
  18. Multicenter, Retrospective Study to Evaluate Necitumumab Plus Cisplatin and Gemcitabine After Immune Checkpoint Inhibitors in Advanced Squamous Cell Lung Cancer in Japan: The NINJA Study, JTO CLINICAL AND RESEARCH REPORTS, 4(12), 202312
  19. Hypoxia-inducible factor 1a modulates interstitial pneumonia-mediated lung cancer progression, JOURNAL OF TRANSLATIONAL MEDICINE, 21(1), 20231127
  20. Nestin and Notch3 collaboratively regulate angiogenesis, collagen production, and endothelial-mesenchymal transition in lung endothelial cells, CELL COMMUNICATION AND SIGNALING, 21(1), 20230921
  21. Exhaled Nitric Oxide and Olfactory Dysfunction in Patients with Asthma: Association with Chronic Rhinosinusitis, MEDICINA-LITHUANIA, 59(10), 202310
  22. Effect of Dupilumab in a Patient With Severe Asthma Complicated With Recurrent Anaphylaxis: A Case Report, JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY, 33(3), 230-232, 202306
  23. Clinical characteristics of extrapulmonary nontuberculous mycobacteria infections in comparison with pulmonary infections: A single-center, retrospective study in Japan, JOURNAL OF INFECTION AND CHEMOTHERAPY, 29(9), 875-881, 202309
  24. Serum and bronchoalveolar lavage fluid levels of soluble B7H3 in patients with interstitial lung diseases, RESPIRATORY MEDICINE, 212, 202306
  25. ★, Predictive value of serum high-mobility group box 1 levels for checkpoint inhibitor pneumonitis, RESPIROLOGY, 28(4), 380-388, 202304
  26. Preserved ratio impaired spirometry with or without restrictive spirometric abnormality, SCIENTIFIC REPORTS, 13(1), 20230220
  27. A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy, LUNG CANCER, 177, 44-50, 202303
  28. Association between Plasminogen Activator Inhibitor-1 and Osimertinib Tolerance in EGFR-Mutated Lung Cancer via Epithelial-Mesenchymal Transition, CANCERS, 15(4), 202302
  29. ★, Association of the RAGE/RAGE-ligand axis with interstitial lung disease and its acute exacerbation, RESPIRATORY INVESTIGATION, 60(4), 531-542, 202207
  30. Association Between Patient Preference for Inhaler Medications and Asthma Outcomes, JOURNAL OF ASTHMA AND ALLERGY, 15, 1539-1547, 2022
  31. Dupilumab as an adjunct treatment for a patient with steroid-dependent immunoglobulin G4-related disease complicated by asthma: a case report, JOURNAL OF ASTHMA, 59(12), 2395-2401, 20221110
  32. ★, Predictive role of circulatory levels of high-mobility group box 1 for radiation pneumonitis in patients with non-small cell lung cancer treated with definitive thoracic radiotherapy, INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 27(11), 1698-1705, 202211
  33. Pneumonia and Meningoencephalitis Due to Varicella-zoster Virus Reinfection and Epstein-Barr Virus Reactivation in a Patient with Rheumatoid Arthritis, INTERNAL MEDICINE, 61(19), 2961-2965, 2022
  34. Characteristic computed tomography features in mesenchymal-epithelial transition exon14 skipping-positive non-small cell lung cancer, BMC PULMONARY MEDICINE, 22(1), 20220630
  35. ★, Role of Soluble Receptor for Advanced Glycation End Products in Postoperative Fibrotic Lung Injury, ANNALS OF THORACIC SURGERY, 113(5), 1617-1623, 202205
  36. Vocal cord dysfunction detected by a three-dimensional image of dynamic change in respiratory resistance in a patient with difficult-to-treat asthma: a case report, JOURNAL OF ASTHMA, 59(6), 1157-1161, 20220603
  37. Phase 2 study of first-line pembrolizumab monotherapy in elderly patients with non-small-cell lung cancer expressing high PD-L1, THORACIC CANCER, 13(11), 1611-1618, 202206
  38. Primary Pulmonary Mucosa-associated Lymphoid Tissue Lymphoma with the High Expression of IgG4, INTERNAL MEDICINE, 61(7), 1043-1048, 2022
  39. Tolerability and efficacy of IMpower133 regimen modified for dialysis patients with extensive-stage small cell lung cancer: Two case reports, THORACIC CANCER, 12(21), 2956-2960, 202111
  40. Pulmonary Alveolar Proteinosis with Severe Respiratory Failure Improved by Segmental Lung Lavage with Fiberoptic Bronchoscopy under General Anesthesia, INTERNAL MEDICINE, 61(3), 389-393, 2022
  41. Pneumatosis Intestinalis following Radiation Esophagitis during Chemoradiotherapy for Lung Cancer: A Case Report, CASE REPORTS IN ONCOLOGY, 14(3), 1454-1459, 2021
  42. Accelerated decline in lung function in adults with a history of remitted childhood asthma, EUROPEAN RESPIRATORY JOURNAL, 59(1), 20220101
  43. First-line osimertinib treatment in a patient with lung adenocarcinoma with coexisting epidermal growth factor receptor G719S and de novo T790M mutations, THORACIC CANCER, 13(5), 771-774, 202203
  44. ★, AGER gene polymorphisms and soluble receptor for advanced glycation end product in patients with idiopathic pulmonary fibrosis., Respirology., 22(5), 965-971, 2017
  45. Obstinate hyponatremia and hypoglycemia caused by pituitary metastasis of lung cancer, 2(3), 279-283, 2013
  46. A Case of Asian Variant Intravascular Large B-cell Lymphoma Diagnosed Based on a Thoracoscopic Lung Biopsy That Exhibited Remission and Exacerbation on Computed Tomography, 53(2), 99-103, 2013
  47. Thymic Carcinoma Treated with Carboplatin and Nab-paclitaxel as Second-line Chemotherapy, 74(8), 900-908, 2015
  48. ★, AGER rs2070600 polymorphism elevates neutrophil-lymphocyte ratio and mortality in metastatic lung adenocarcinoma, ONCOTARGET, 8(55), 94382-94392, 20171107
  49. Nivolumab-induced severe pancytopenia in a patient with lung adenocarcinoma, LUNG CANCER, 119, 21-24, 201805
  50. Gene expression profiling of idiopathic interstitial pneumonias (IIPs): identification of potential diagnostic markers and therapeutic targets, BMC Med Genet, 18(1), 88, 2017
  51. Bevacizumab with Single-agent Chemotherapy in Previously Treated Non-squamous Non-small-cell Lung Cancer: Phase II Study, IN VIVO, 32(5), 1155-1160, 2018
  52. Alternate-day administration of S-1 for elderly patients with advanced non-small-cell lung carcinoma: A prospective feasibility study, MOLECULAR AND CLINICAL ONCOLOGY, 9(5), 539-544, 201811
  53. Serial measurements of KL-6 for monitoring activity and recurrence of interstitial pneumonia with anti-aminoacyl-tRNA synthetase antibody A retrospective cohort study, MEDICINE, 97(49), 201812
  54. Anti-KL-6/MUC1 monoclonal antibody reverses resistance to trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity by capping MUC1, CANCER LETTERS, 442, 31-39, 2019
  55. High preoperative C-reactive protein level is a risk factor for acute exacerbation of interstitial lung disease after non-pulmonary surgery, MEDICINE, 98(5), 201902
  56. Cerebral embolism during edoxaban administration for venous thromboembolism in a patient with lung adenocarcinoma A case report, MEDICINE, 98(12), 201903
  57. Inhibition of PAI-1 limits chemotherapy resistance in lung cancer through suppressing myofibroblast characteristics of cancer-associated fibroblasts, JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 23(4), 2984-2994, 201904
  58. Performance Status Is a Risk Factor for Depression before the Diagnosis of Lung Cancer Patients, INTERNAL MEDICINE, 58(7), 915-920, 2019
  59. Suplatast tosilate reduces radiation-induced lung injury in mice through suppression of oxidative stress, FREE RADICAL BIOLOGY AND MEDICINE, 136, 52-59, 20190520
  60. Comparison of anti-aminoacyl-tRNA synthetase antibody-related and idiopathic non-specific interstitial pneumonia, RESPIRATORY MEDICINE, 152, 44-50, 201906
  61. Pre-existing interstitial lung abnormalities are risk factors for immune checkpoint inhibitor-induced interstitial lung disease in non-small cell lung cancer, RESPIRATORY INVESTIGATION, 57(5), 451-459, 201909
  62. C-C Motif Chemokine Ligand 15 May Be a Useful Biomarker for Predicting the Prognosis of Patients with Chronic Hypersensitivity Pneumonitis, RESPIRATION, 98(3), 212-220, 201909
  63. Chemotherapy-associated Acute Exacerbation of Interstitial Lung Disease Shortens Survival Especially in Small Cell Lung Cancer, ANTICANCER RESEARCH, 39(10), 5725-5731, 201910
  64. Non-small Cell Lung Cancer Treated by an Anti-programmed Cell Death-1 Antibody without a Flare-up of Preexisting Granulomatosis with Polyangiitis, INTERNAL MEDICINE, 58(21), 3129-3132, 2019
  65. Albumin-globulin ratio is a predictive biomarker of antitumor effect of anti-PD-1 antibody in patients with non-small cell lung cancer, INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 25(1), 74-81, 20200101
  66. Treatment rationale and design of the PROLONG study: safety and efficacy of pembrolizumab as first-line therapy for elderly patients with non-small cell lung cancer, JOURNAL OF THORACIC DISEASE, 12(3), 1079-1084, 20200301
  67. ★, Serum high-mobility group box 1 is associated with the onset and severity of acute exacerbation of idiopathic pulmonary fibrosis, RESPIROLOGY, 25(3), 275-280, 20200301
  68. ★, Reduced endogenous secretory RAGE in blood and bronchoalveolar lavage fluid is associated with poor prognosis in idiopathic pulmonary fibrosis, RESPIRATORY RESEARCH, 21(1), 20200611
  69. A Case of Non-small Cell Lung Cancer Treated by an Anti-programmed Cell Death-1 Antibody without a Flare-up of Preexisting Granulomatosis with Polyangiitis., Intern Med., 58, 3129-3132, 2019
  70. ★, Serum high-mobility group box 1 as a predictive marker for cytotoxic chemotherapy-induced lung injury in patients with lung cancer and interstitial lung disease, RESPIRATORY MEDICINE, 172, 20200828
  71. Extent of pulmonary fibrosis on high-resolution computed tomography is a prognostic factor in patients with pleuroparenchymal fibroelastosis, RESPIRATORY INVESTIGATION, 58(6), 465-472, 20200803
  72. Coexisting TIF1 gamma-positive Primary Pulmonary Lymphoepithelioma-like Carcinoma and Anti-TIF1 gamma Antibody-positive Dermatomyositis, INTERNAL MEDICINE, 59(20), 2553-2558, 20201015
  73. Association of Preexisting Interstitial Lung Abnormalities With Immune Checkpoint Inhibitor-Induced Interstitial Lung Disease Among Patients With Nonlung Cancers, JAMA NETWORK OPEN, 3(11), 20201112
  74. Clinical significance of BIM deletion polymorphism in chemoradiotherapy for non-small cell lung cancer, CANCER SCIENCE, 112(1), 369-379, 20201112
  75. Correlations of forced oscillometric bronchodilator response with airway inflammation and disease duration in asthma, CLINICAL RESPIRATORY JOURNAL, 15(1), 48-55, 20210914
  76. Two Cases of Cranial Nerve Metastasis Treated with Radiotherapy and Chemotherapy in Patients with Lung Adenocarcinoma, CASE REPORTS IN ONCOLOGY, 13(3), 1495-1500, 20201217
  77. Alectinib-induced Immune Hemolytic Anemia in a Patient with Lung Adenocarcinoma, INTERNAL MEDICINE, 60(4), 611-615, 20200930
  78. Concomitant emphysema might increase the false-negative rate of urinary antigen tests in patients with pneumococcal pneumonia: results from a retrospective study, EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 40(4), 871-877, 20201104
  79. Autoantibody Positivity Is a Risk Factor for Chemotherapy-induced Exacerbation of Interstitial Pneumonia in Lung Cancer, ANTICANCER RESEARCH, 41(3), 1497-1506, 20210301
  80. Pulmonary lymphangitic carcinomatosis from recurrent gastric cancer 19 years after primary resection: a case report, CLINICAL JOURNAL OF GASTROENTEROLOGY, 14(2), 484-488, 20210401
  81. Pulmonary arteriovenous malformation exhibiting recanalization >10 years after coil embolization Two case reports, MEDICINE, 99(2), 20200101
  82. Prognostic Significance of EGFR Gene Mutation in Patients With EGFR Mutated Non-small Cell Lung Cancer Who Received Best Supportive Care Alone, ANTICANCER RESEARCH, 41(5), 2661-2667, 20210501
  83. ★, Predictive role of circulatory HMGB1 in postoperative acute exacerbation of interstitial lung disease in lung cancer patients, SCIENTIFIC REPORTS, 11(1), 20210512
  84. Risk factors associated with increased discontinuation rate of trimethoprim-sulfamethoxazole used as a primary prophylaxis for Pneumocystis pneumonia: A retrospective cohort study, PULMONARY PHARMACOLOGY & THERAPEUTICS, 67, 20210208
  85. D-dimer can be a diagnostic marker for cisplatin-related aortic thrombosis A case report, MEDICINE, 100(7), 20210219
  86. A machine-learning based approach to quantify fine crackles in the diagnosis of interstitial pneumonia A proof-of-concept study, MEDICINE, 100(7), 20210219
  87. IL-18 binding protein can be a prognostic biomarker for idiopathic pulmonary fibrosis, PLOS ONE, 16(6), 20210604
  88. Quantitative parameters of lymphocyte nuclear morphology in bronchoalveolar lavage fluid as novel biomarkers for sarcoidosis, ORPHANET JOURNAL OF RARE DISEASES, 16(1), 20210703
  89. A Phase II Study to Assess the Efficacy of Osimertinib in Patients With EGFR Mutation-positive NSCLC Who Developed Isolated CNS Progression (T790M-negative or Unknown) During First- or Second-generation EGFR-TKI or Systemic Disease Progression (T790M-negative) After Treatment With First- or Second-generation EGFR-TKI and Platinum-based (WJOG12819L), CLINICAL LUNG CANCER, 22(4), 376-380, 20210125
  90. Antifibrotic effect of lung-resident progenitor cells with high aldehyde dehydrogenase activity, STEM CELL RESEARCH & THERAPY, 12(1), 20210823
  91. Human bone marrow-derived mesenchymal stromal cells cultured in serum-free media demonstrate enhanced antifibrotic abilities via prolonged survival and robust regulatory T cell induction in murine bleomycin-induced pulmonary fibrosis, STEM CELL RESEARCH & THERAPY, 12(1), 20210916
  92. Analysis of microRNA Expression in Liquid-Based Cytology Samples May Be Useful for Primary Lung Cancer Diagnosis, AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 156(4), 644-652, 202110
  93. Association between glucose intolerance and chemotherapy-induced lung injury in patients with lung cancer and interstitial lung disease, CANCER CHEMOTHERAPY AND PHARMACOLOGY, 88(5), 857-865, 202111
  94. Rapid changes of nailfold capillary abnormalities during treatment for a patient with dermatomyositis complicated by lung cancer: a case report, MODERN RHEUMATOLOGY CASE REPORTS, 5(1), 95-100, 20210102

Awards

  1. 2024/02/23, JSMO2024 Award, 日本臨床腫瘍学会, Prospective observational study to identify a predictive blood marker for checkpoint inhibitor pneumonitis (CS-Lung 004)
  2. 2021/11/21, JRS Young Scientist Award, APSR, The role of circulatory high-mobility group box 1 for predicting checkpoint inhibitor pneumonitis caused by anti-PD-1/PD-L1 antibody monotherapy

External Funds

Acceptance Results of Competitive Funds

  1. KAKENHI(Grant-in-Aid for Early-Career Scientists), 2022, 2025
  2. 2021, 2021
  3. 2020, 2021
  4. 2020
  5. KAKENHI(Grant-in-Aid for Early-Career Scientists), 2018, 2020

Social Activities

History as Peer Reviews of Academic Papers

  1. 2024, Internal Medicine, Others, 1
  2. 2024, Health Science Reports, Others, 1
  3. 2024, BMC cancer, Others, 1
  4. 2024, BMC Medical Genomics, Others, 1
  5. 2024, BMC pulmonary medicine, Others, 3
  6. 2024, Respiratory Research, Others, 2